Jonathan R. Lambert
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.
Journal: Science translational medicine
Published: July 01, 2026
Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.
Journal: Cancer discovery
Published: February 26, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.
Journal: British journal of haematology
Published: February 25, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.
Journal: British journal of haematology
Published: October 10, 2025
Adolescent and young adult patients with 'Philadelphia negative' myeloproliferative neoplasms: a real world, UK tertiary-centre study.
Journal: Current research in translational medicine
Published: June 02, 2025
Echocardiography in cardio-oncology: optimising service delivery.
Journal: Echo research and practice
Published: April 06, 2025
UK guidelines for the investigation and management of eosinophilia in returning travellers and migrants.
Journal: The Journal of infection
Published: October 10, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Journal: British journal of haematology
Published: April 19, 2024
Dog Owners' Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey.
Journal: Animals : an open access journal from MDPI
Published: February 15, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
Journal: HemaSphere
Published: February 13, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: October 16, 2023
Last Updated: 09/26/2026